Esclerose sistémica - perspectivas actuais

Autores

  • Ana Paula Vilas Serviço de Medicina 1 do Hospital Egas Moniz, Lisboa
  • Manuela Zita Veiga Serviço de Medicina 1 do Hospital Egas Moniz, Lisboa
  • Pedro Abecasis Serviço de Medicina 1 do Hospital Egas Moniz, Lisboa

Palavras-chave:

Esclerose sistémica, classificação, diagnóstico, tratamento, prognóstico, esclerodermia

Resumo

A esclerose sistémica (ES) é uma doença relativamente rara, caracterizada por diferentes graus de fibrose da pele e dos órgãos internos. Pode ser dividida em dois grupos principais: ES limitada e ES difusa. Estes diferenciam-se, sobretudo, pela extensão do envolvimento cutâneo e caracterizam-se por evoluções e prognósticos diferentes. Ao longo dos anos ocorreram várias alterações a nível de conceitos relacionados com a ES. A uniformização destes é de grande importância, já que permite a realização de estudos em que se comparam grupos de doentes de centros diferentes, facilitando assim o melhor conhecimento desta entidade patológica. Apesar de a ES ser conhecida desde o século XVIII e ser reconhecida como patologia multissistémica desde o século XIX (antes considerava-se a esclerose cutânea – esclerodermia – como uma entidade patológica, a que se associavam outras doenças gastrointestinais, pulmonares, etc.), a sua etiologia continua a ser desconhecida e a sua patogénese não totalmente esclarecida. Isto leva a que não exista um tratamento específico e, portanto, curativo. Apesar disso, hoje já é possível controlar muitas das manifestações da ES. O aparecimento dos inibidores do enzima de conversão da angiotensina (IECA) na década de oitenta, por exemplo, permitiu controlar aquela que era até então a maior causa de morte na ES, a crise renal esclerodérmica. Este e outros novos avanços têm permitido melhorar a qualidade de vida destes doentes, bem como a sua esperança de vida. Neste trabalho abordam-se as perspectivas actuais de tratamento desta patologia e dos seus diferentes aspectos.

Downloads

Não há dados estatísticos.

Referências

Altman RD, Medsger TA Jr. Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-411.

Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA Jr. Incidence of systemic sclerosis in Allegheny County, Pennsylvania: a twenty-year study of hospital diagnosed cases –1963-1082. Arthritis Rheum 1997; 40: 441-445.

Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumat 1988; 15: 276-283.

Byran C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of skleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheum 1996; 35: 1122-1126.

Tuffanelli DL, Winkelmann RK. Systemic scleroderma: a clinical study of 727 cases. Arch Dermatol 1961; 84: 359-371.

Barnett AJ, Coventry DA. Scleroderma: clinical features, course of illness and response to treatment in 61 cases. Med J Aust 1969; 1:992-1001.

LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.

Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590.

Rodnan GP, Fennell RH Jr. Progressive systemic sclerosis sine scleroderma. JAMA 1962; 180:97-102.

Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serological features and survival in forty-eight patients. Arthritis Rheum 2000; 43: 444-451.

Black C, Dieppe P, Huskisson T, Hart ED. Regressive systemic sclerosis. Ann Rheum Dis 1986; 45: 384-388.

Fitzgerald O, Hess EV, O’Connor GT, Spencer-Green G. Prospective study of the evolution of Raynaud’s phenomenon. Am J Med 1988; 84: 718-726.

Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenic event underlining skin lesions in avian and human scleroderma. J Clin Invest 1996; 98: 785-792.

Prescott RJ, Freemont AJ, Jones CJP, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166: 255-263.

Orfanos SE, Psevdi E, Stratigis N et al. Pulmonary capillary endothelial dysfunction in early systemic sclerosis. Arthritis Rheum 2001; 44: 902-911.

Artlett CM, Smith BJ, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Eng J Med 1998; 338: 1186-1191.

Nelson JL. Microchimerism and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 1998; 10: 564-571.

Follansbee WP, Curtiss EI, Medsger TA Jr et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984; 310: 142-148.

Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis. Circulation 1976; 53:

-490.

Alexander EL, Firestein GS, Weiss JL et al. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Int Med 1986; 105: 661-668.

Furst DE, David JA, Clements PJ, Chopra SK, Theofilopoulos AN, Chia D. Abnormalities of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis. Arthritis Rheum 1981; 24: 1403-1408.

MacGregor AJ, Canavan R, Knight C et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 2001; 40: 453-459.

Roberts NK, Cabeen WR, Moss J, Clements PJ, Furst DE. The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. Ann Intern Med 1981; 94: 38-40.

Steen VD, Constantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 352-357.

Steen VD, Medsger TA Jr, Osial TA, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development in progressive systemic sclerosis. Am J Med 1984; 76: 779-786.

Helfrich DJ, Banner B, Steen VD, Medsger TA Jr. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989; 32: 1128-1134.

Traub YM, Shapiro AP, Rodnan GP et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis: review of a 25-year experience with 68 cases. Medicine 1983; 62: 335- 352.

Lock G, Holstege A, Lang B, Schölmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol 1997; 92: 763-771.

Zamost BJ, Hirschberg J, Ippoliti AF, Furst DE, Clements PJ, Weinstein WM. Esophagitis in scleroderma. Gastroenterology 1987; 92: 421-428.

Johnson DA, Drane WE, Curran J et al. Pulmonary disease in progressive systemic sclerosis: a complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989; 149: 589-593

Troshinsky MB, Kane GC, Varga J et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 1994; 121: 6-10.

Marie I, Levesque H, Ducrotté P et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 2001; 96: 77-83.

Trezza M, Krogh K, Egekvist H, Bjerring P, Laurberg S. Bowel problems in patients with systemic sclerosis. Scand J Gastroenterol 1999; 34: 409-413.

Averbuch-Heller L, Steiner I, Abramsky O. Neurologic manifestations of progressive systemic sclerosis. Arch Neurol 1992; 49: 1292-1295.

Cutolo M, Nobili F, Sulli A et al. Evidence of cerebral hypoperfusion in scleroderma patients. Rheumatology 2000; 39: 1366-1373.

Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203.

Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998; 37: 15-20.

Tan FK, Arnett FC, Reveille JD et al. Autoantibodies to fibrillarin 1 in systemic sclerosis. Arthritis Rheum 2000; 43: 2464-2471.

Okano Y, Steen VD, Medsger TA Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993; 119: 1005-1013.

Grigolo B, Mazzetti I, Meliconi R et al. Anti-topoisomerase II a autoantibodies in systemic sclerosis – association with pulmonary hypertension and HLA-B35. Clin Exp Immunol 2000; 121: 539-543.

Chen ZY, Silver RM, Ainsworth SK, Dobson RL, Rust P, Maricq HR. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. Am J Med 1984; 77: 812-822.

Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000; 27: 155-160.

Harrison NK, Glanville AR, Strickland B et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respiratory Medicine 1989; 83: 403-414.

Wells AU, Hansell DM, Corrin B et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992; 47: 738-742.

Wells AU, Hansell DM, Rubens MB et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40: 1229-1236.

Lonzetti LS, Joyal F, Raynauld J-P et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001; 44: 735-738.

Clements PJ, Furst DE, Wong WK et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis. Arthritis Rheum 1999; 42: 1194-203.

Kahan A, Bour B, Couturier D, Amor B, Menkes CJ. Nifedipine and esophageal dysfunction in progressive systemic sclerosis: a controlled manometric study. Arthritis Rheum 1985; 28: 490-495.

Jean F, Aubert A, Bloch F et al. Effects of diltiazem versus nifedipine on lower esophageal sphincter pressure in patients with progressive systemic sclerosis. Arthritis Rheum 1986; 29: 1054-1055.

White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-954.

Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37: 729-735.

Steen VD, Lanz JK, Conte C, Owens GR, Medsger TA Jr. Therapy for severe interstitial lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1290-1296.

Font J, Ramos-Casals M, Cervera R, Jiménez S, Espinosa G, Ingelmo

M. Guías clínicas de diagnóstico y tratamiento de las enfermedades autoinmunes sistémicas. Barcelona: mra ediciones. 2001: 60.

Kubo M, Vensak J, Dauber J, Keenan R, Griffith B, McCurry K. Lung transplantation in patients with scleroderma. J Heart Lung Transplantation 2001; 20: 174-175.

Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Eng J Med 1992; 327: 76-81.

Lopez-Ovejero JA, Saal SD, D’Angelo WA, Cheigh JS, Stenzel KH, Laragh JH. Reversal of vascular and renal crises of scleroderma with oral angiotensin-converting-enzyme blockage. N Eng J Med 1979; 300: 1417-1419.

Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacteria overgrowth in scleroderma. N Eng J Med 1991; 325: 1461-1467.

A Tyndall. Hematopoietic stem cell transplantation in the treatment of severe autoimmune disease. In: Dicke KA, Keating A, eds. Autologous blood and marrow transplantation X: Proceedings of the tenth International Symposium. Charlottsville, Carden Jennings Publishing Co., Ltd. 2001: 203-205.

Binks M, Passweg JR, Furst D et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-584.

McSweeney PA, Furst DE, Nash RA et al. High-dose immunosuppressive therapy as treatment for severe systemic sclerosis. In: Dicke KA, Keating A, eds. Autologous blood and marrow transplantation X: Proceedings of the tenth International Symposium. Charlottsville, Carden Jennings Publishing Co., Ltd. 2001: 213-218.

Tyndall A, Gratwohl A. Immune ablation and stem-cell therapy in autoimmune disease: clinical experience. Arthritis Res 2000; 2:

-280.

Abu-Shakra M, Lee P. Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol 1995; 22: 2100-2102.

Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57: 682-686.

Byran C, Khight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma. Arthritis Rheum 1999; 42: 2660-2665.

Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998; 37: 750-755.

Nagy Z, Czirjak L. Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol 1997; 16: 454-460.

Clements PJ, Hurwitz EL, Wong WK et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis. Arthritis Rheum 2000; 43: 2445-2454.

Clements PJ, Lachenbruch PA, Cheng S, Simmons M, Sterz M, Furst DE. Skin score: a semiquantitive measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990; 33: 1256-1263

Ficheiros Adicionais

Publicado

28-06-2002

Como Citar

1.
Vilas AP, Veiga MZ, Abecasis P. Esclerose sistémica - perspectivas actuais. RPMI [Internet]. 28 de Junho de 2002 [citado 16 de Junho de 2024];9(2):111-20. Disponível em: https://revista.spmi.pt/index.php/rpmi/article/view/1939

Edição

Secção

Artigos de Revisão

Artigos mais lidos do(s) mesmo(s) autor(es)